Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 34 of 100, showing 5 Applications out of 497 total, starting on record 166, ending on 170

# Protocol No Study Title Investigator(s) & Site(s)

166.

ECCT/22/01/01   ASTEFANIA
    A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ATEZOLIZUMAB OR PLACEBO AND TRASTUZUMAB EMTANSINE FOR HER2-POSITIVE BREAST CANCER AT HIGH RISK OF RECURRENCE FOLLOWING PREOPERATIVE THERAPY   
Principal Investigator(s)
1. Mansoor Saleh
2. Fredrick Chite Asirwa
Site(s) in Kenya
1. Aga Khan University, Nairobi (Nairobi City county)
2. International Cancer Institute (Uasin Gishu county)
 
View

167.

ECCT/22/01/06   AIKILI Technology
    Feasibility and accuracy of nanosensor-based breast cancer diagnosis at the point-of-care-AIKILI technology       
Principal Investigator(s)
1. Laura Kelley Kelley
Site(s) in Kenya
Aga Khan University Hospital, Nairobi.
 
View

168.

ECCT/22/01/03   lidERA
    A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared with Physician’s Choice of Adjuvant Endocrine Monotherapy in Patients with Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer   
Principal Investigator(s)
1. Mansoor Saleh
Site(s) in Kenya
1. International Cancer Institute (ICI) (Uasin Gishu county)
2. Aga Khan University Hospital (Nairobi City county)
 
View

169.

ECCT/21/11/05   SOLIDARITY TRIAL PLUS
    An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care   
Principal Investigator(s)
1. loice Ombajo
Site(s) in Kenya
1. KENYATTA NATIONAL HOSPITAL SITE (Nairobi City county)
2. The Nairobi Hospital (Nairobi City county)
 
View

170.

ECCT/21/11/01   VAT 00008
    A parallel-group, Phase III, multi-stage, modified double-blind, multi-armed study to assess the efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (monovalent and bivalent) for prevention against COVID-19 in adults 18 years of age and older   
Principal Investigator(s)
1. Walter Godfrey Jaoko
Site(s) in Kenya
1. Kenya Medical Research Institute (Kisumu county)
2. KEMRI/Walter Reed Project Research Center (Kericho county)
3. KEMRI/CCR Partners in Health R&D (PHRD) (Kiambu county)
4. KEMRI CMR (Kisumu county)
5. Kenya Medical Research Institute (Nairobi City county)
6. KEMRI-UAMRD-A/K, Kombewa Clinical Research Center (Kisumu county)
7. Moi University Clinical Research Centre (Uasin Gishu county)
8. Aga Khan University Hospital (Nairobi City county)
9. KEMRI CCR-Butere County Hospital Site (Kakamega county)
10. Ganjoni Clinic (Mombasa county)
 
View